How this fits in {#s1}
================

High-risk prescribing places patients at increased risk of ADEs and is increasingly common. The SPACE intervention combines practice prescribing audit and feedback to doctors with a mail-out to at risk patients to prompt medicines review. SPACE can be delivered within existing primary care infrastructure. Findings from this pilot study suggest SPACE supports safer prescribing in routine general practice in the short term; however a randomised trial is needed to confirm this.

Introduction {#s2}
============

High-risk prescribing places patients at increased risk of an ADE. ADEs result in many avoidable hospital admissions every year, disrupting people's lives and draining precious health resources.^[@bib1]--[@bib9]^ The single greatest predictor for high-risk prescribing and ADEs is the number of medicines a person is taking.^[@bib10]^ High-risk prescribing and ADEs are increasingly common as more people are living longer and taking more medicines for multiple chronic conditions. Commonly prescribed medicines account for most ADE admissions, notably NSAIDs, antiplatelet medicines, and anticoagulants, which together account for one-third of all ADE admissions.^[@bib3],[@bib4]^ Most ongoing prescribing occurs in general practice.

Safe prescribing entails regular review of medicines, and stopping or starting medicines as indicated. High-risk prescribing may be justified by the individual circumstances of a patient, but regular review of medicines is important to ensure ongoing safety. There is good evidence to guide safe prescribing, but a gap remains between existing evidence and current prescribing practice. Translating evidence into practice is difficult. There are many barriers to regular medicines review in routine general practice.^[@bib11]^ The large variation in prescribing between practices and regions suggests room for improvement.^[@bib12]--[@bib14]^

The scale of the problem of high-risk prescribing and avoidable ADEs has prompted searches internationally for ways to support safer prescribing in general practice.^[@bib15]^ There is good evidence that audit and feedback can change practice, especially when used in ongoing quality improvement programmes that also include education and incentives.^[@bib15]--[@bib24]^ For example, the pharmacist-led information technology intervention for medication error (PINCER) trial in England used a pharmacist to deliver educational outreach and feedback to GPs;^[@bib20]^ the Data-driven Quality Improvement in Primary Care (DQIP) trial in Scotland used educational outreach, informatics to facilitate medicines review and provide regular feedback, and financial incentives;^[@bib18],[@bib23]^ and the Optimizing Prescribing for Older People in Primary Care, a cluster-randomised controlled trial (OPTI-SCRIPT trial) in the Republic of Ireland used academic detailing by a pharmacist and a web-guided medication review.^[@bib24],[@bib25]^ There is also the Australian Veterans' Medicines Advice and Therapeutics Education Service (MATES) quality improvement programme that combines practice prescribing audits and patient-based feedback and education to doctors, with a practice mail-out to at-risk patients.^[@bib19]^

The most effective, cost-effective, and practical approach to safer prescribing in New Zealand is not yet known. In New Zealand, general practices are organised into primary health organisations (PHOs) that deliver most quality improvement initiatives. Some PHOs employ clinical advisory pharmacists to support prescribing. GPs report suffering from alert fatigue, and that educational support and financial incentives would support safer prescribing.^[@bib11]^ However, financial incentives may not be sustainable and can have unintended consequences. Based on the existing knowledge base and qualitative findings, the MATES intervention was adapted to the New Zealand primary care context creating the SPACE intervention.^[@bib26]^

SPACE comprises an automated practice prescribing audit to identify and generate for each doctor a list of patients with high-risk prescribing; an outreach visit from a clinical advisory pharmacist to deliver a group educational session, and to meet one-on-one with each doctor to go through their list of patients and to indicate in a tick-box an intended action for each patient (no change/change prescribing/letter to patient); and an automated practice mail-out to selected patients of a medicines information brochure and a letter encouraging patients to discuss their medicines when they next see their doctor. SPACE was designed to prompt medicines review and support safer prescribing in routine practice. All prescribing decisions are made as usual by the doctor together with the patient. SPACE differs from MATES in that it is not part of an ongoing quality improvement programme, targets all doctors and at-risk patients in a practice, and has no national call centre. SPACE does not use financial incentives or provide regular updates and comparators. The novel aspect of SPACE is the attempt to engage patients through a practice mail-out. The utility and acceptability of SPACE have been confirmed.^[@bib26]^

The authors worked with one PHO to pilot the SPACE intervention in two practices in preparation for a larger cluster RCT. The specific objectives of the pilot study were to optimise delivery of the SPACE intervention; test data management processes and outcome measures; and to assess whether SPACE reduced the rate of high-risk prescribing.

Method {#s3}
======

The high-risk prescribing topic chosen for this pilot study was NSAIDs and antiplatelet medicines.^[@bib21]^ High-risk prescribing of these medicines has been studied in previous trials.^[@bib18]^

Setting & participants {#s3-1}
----------------------

The setting was two general practices from one PHO in Auckland, New Zealand. Eligibility was restricted to practices using MedTech practice management software. The pharmacist recruited two practices, one medium and one small, from the PHO network of member practices. Since patients may receive prescriptions from any GP in a practice, informed consent was obtained from all GPs in each participating practice.

Study participants were all patients who were vulnerable at baseline; that is, those patients at increased risk of an ADE when prescribed NSAIDs or antiplatelet medicines as set out in [Box 1](#B1){ref-type="table"}. The study was focused on older adults, but not restricted to this group as younger patients who fitted the categories not dependent on age, such as history of peptic ulcer ever or renal impairment (most recent estimated glomerular filtration rate \[eGFR\] \<60), were included. A computer query was run over each practice database of enrolled patients to identify patients fulfilling eligibility criteria for 'vulnerability' to ADE according to the demographic, clinical, and prescribing criteria described in [Box 1](#B1){ref-type="table"}. A second database query identified those 'vulnerable' individuals who also received 'high risk prescribing' in the previous 14 weeks according to prescribing data ([Box 1](#B1){ref-type="table"}). These queries can be run remotely by the PHO or by Dr Info, an organisation contracted by the practices to run clinical audits for the practices' benefit. Individual patient consent to participation was not sought because all treatment decisions were made as usual by the GP together with the patient, and because outcomes data were collected in routine patient care and were anonymised prior to extraction for analysis and linking.

###### Categories of vulnerable patients and high-risk prescribing of NSAIDs and antiplatelet medicines^[@bib17]^

  Type of adverse drug event                                                                 Vulnerable patients (at increased risk of ADE)                            High-risk prescribing^a^
  ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Gastrointestinal bleed                                                                     Prior peptic ulcer ever                                                   NSAID or aspirin without gastroprotection, in patient with prior peptic ulcer
  Aged ≥75 years                                                                             NSAID without gastroprotection, in patient ≥75 years                      
  Aged ≥65 years prescribed aspirin                                                          NSAID without gastroprotection, in patient ≥65 years taking aspirin       
  Clopidogrel without gastroprotection, in patient ≥65 years taking aspirin                                                                                            
  Prescribed oral anticoagulant                                                              NSAID without gastroprotection, in patient taking an oral anticoagulant   
  Aspirin or clopidogrel without gastroprotection, in patient taking an oral anticoagulant                                                                             
  Renal impairment                                                                           Prescribed both renin-angiotensin system blocker and diuretic             NSAID, in patient taking both renin-angiotensin system blocker and diuretic
  Chronic kidney disease (most recent eGFR \<60)                                             NSAID, in patient with chronic kidney disease (eGFR \<60)                 
  Cardiac failure                                                                            Heart failure ever                                                        NSAID, in patient with history of heart failure

^a^Medicines prescribed within the previous 14 weeks. ADE = adverse drug event. eGFR = estimated glomerular filtration rate. NSAID = nonsteroidal anti-inflammatory drug. 

Intervention {#s3-2}
------------

The SPACE intervention comprises:

1.  a practice audit to identify and generate for each GP a list of patients with high-risk prescribing of NSAIDs and/or antiplatelet medicines;

2.  an outreach visit by a clinical advisory pharmacist to provide:a group educational session to GPs about the prescribing topic;a one-on-one meeting with GPs to go through their list of at-risk patients and to indicate in a tick-box the intended action for each patient (no action/review medicines/mail-out to patient); and

3.  a practice mail-out to selected patients containing a medicines information brochure and a letter encouraging patients to discuss their medicines when they next see their doctor.

Outcome measures {#s3-3}
----------------

The outcome measures were process outcomes and high-risk prescribing outcomes. Process outcomes included the success and time taken to deliver the intervention; and the data extraction, anonymisation, and linking over time. High-risk prescribing outcome measures were the proportion of study participants receiving high-risk prescribing of NSAID and/or antiplatelet medicines at 6 months and 12 months compared with baseline. The primary outcomes were the proportion of study participants (patients who were vulnerable at baseline) who received high risk prescribing of NSAIDs and/or antiplatelet medicines in the 14 weeks prior to each time-point, according to the definitions listed in [Box 1](#B1){ref-type="table"}.

The secondary high-risk prescribing outcome measures included:

1.  the proportion of study participants at increased risk of gastrointestinal ADEs receiving high-risk prescribing of NSAID and/or antiplatelet medicines;

2.  the proportion of study participants at increased risk of renal ADEs receiving high-risk prescribing of NSAID medicines;

3.  the proportion of study participants at increased risk of cardiac ADEs receiving high-risk prescribing of NSAID medicines; and

4.  overall practice rate of high-risk prescribing of NSAIDs and antiplatelet medicines. This included vulnerable patients who were newcomers to the practice at 6 or 12 months, and practice patients who were not previously vulnerable (at increased risk of an ADE) but who became so.

Analyses {#s3-4}
--------

Data on patients were anonymised prior to the data leaving the practice using an encrypted unique patient identifier, the National Health Index (NHI) number, to allow linking over time. Demographic and clinical characteristics of the study practices and patients were described. Outcomes at 6 months and 12 months were compared with baseline, using repeated measures generalised linear mixed models. *P*-values of 0.05 were considered statistically significant. Sensitivity analyses used last value carried forward for those participants who were lost for follow-up.

Results {#s4}
=======

Practice and patient characteristics {#s4-1}
------------------------------------

Practice A included six GPs with 7944 enrolled patients, and Practice B had one GP and 2500 enrolled patients. From the total of 10 444 enrolled patients, 870 (8.3%) individual patients were at increased risk of ADE related to NSAIDs and/or antiplatelet medicines (vulnerable patients) and comprised the study population. [Table 1](#tbl1){ref-type="table"} describes the demographic characteristics of the study population.Table 1.Characteristics of study population (patients who were vulnerable at baseline, that is at increased risk of an adverse drug event with non-steroidal anti-inflammatory drugs and/or antiplatelet medicines^a^) from the two participating general practicesGeneral practice A\
(registered patients: *n *= 7944)General practice B\
(registered patients: *n *= 2500)TotalVulnerable patients^a^, *n* (%)668 (8.6)202 (8.1)870 (8.9)Age, mean (SD)74.9 (11.2)73.2 (12.3)74.5 (11.4)Female, *n* (%)392 (58.7)96 (47.5)488 (56.1)**Ethnicity, *n* (%):** New Zealand European321 (48.1)157 (77.7)478 (54.9) Other European253 (37.9)23 (11.4)276 (31.7) New Zealand Maori7 (1.0)4 (2.0)11 (1.3) Pasifika5 (0.7)1 (0.5)6 (0.7) East Asian29 (4.3)6 (3.0)35 (4.0) Indian12 (1.8)7 (3.5)19 (2.2) Other41 (6.1)4 (2.0)45 (5.2)Number of long-term medicines, mean (SD)4.07 (1.86)1.35 (0.56)3.44 (2.01)[^1]

The practice audits identified 70 individual patients with high-risk prescribing (8.0% of vulnerable patients). Some patients fulfilled more than one of the high-risk prescribing criteria set out in [Box 1](#B1){ref-type="table"}.

Intervention delivery {#s4-2}
---------------------

The PHO clinical advisory pharmacist delivered one-on-one feedback and education to all seven doctors in the two practices. In the group practice, the pharmacist delivered education about the prescribing topic in a group session, which took about 30 minutes, followed by the one-on-one session with each doctor to go through their list of at-risk patients, which took about 15 minutes each.

Overall, the GPs selected 29 of the 70 patients with high-risk prescribing (41.4%) to receive the mail-out. The main reason GPs decided not to send the mail-out to patients was because the high-risk prescribing had already ceased (for example, the NSAID prescription had been for only a short course); other reasons included the patient had transferred to another practice, the NSAID prescription had been for gel, the renal function had improved and eGFR was now \>60, and/or because the GP was not convinced the prescribing was high risk.

Data extraction, encryption, and linkage processes {#s4-3}
--------------------------------------------------

The automated data extraction and encryption processes worked well. There was some refinement in data extraction methods between baseline and 6 months, particularly around the eGFR (changed from 'ever' to 'latest' eGFR \<60). This ensured that prescribing was deemed 'high risk\' only due to the latest eGFR being \<60, and not based on a historically low eGFR. There were 32/870 (3.7%) patients lost to follow-up between baseline and 6 months who were included in the study population due to a low eGFR at baseline, of which only three of 32 were found to have high-risk prescribing where it could not be retrospectively confirmed that the low eGFR was the most recently recorded when the prescribing occurred. This is unlikely to have made a difference to the outcomes presented below.

High-risk prescribing outcomes {#s4-4}
------------------------------

At 6 months there was a significant reduction in the proportion of study participants receiving high-risk prescribing, reducing from 8.0% to 5.8% (*P*\<0.05), even when all those lost to follow-up were assumed to have the same high-risk prescribing status as baseline ([Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). Changes in secondary outcomes showed similar significant improvements, except for those with congestive heart failure, as these rates were already very low at baseline ([Table 2](#tbl2){ref-type="table"}). However, at 12 months the proportion of study participants receiving high-risk prescribing had returned to baseline levels or worse. The overall practice rates of high-risk prescribing did not show a reduction at 6 months, with trends increasing at 12 months ([Table 2](#tbl2){ref-type="table"})

###### Rates of high-risk prescribing at baseline, and 6 and 12 months post-intervention for study population and for practice population overall

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                              Study population^a^   Practice population^b^                                                      
  ----------------------------------------- ----------------- --------------------- ------------------------ ------------------- -------------- --------------- ----------------
  Outcome measure                           Baseline          6-month\              *P*-value                12-month\           *P*-value^c^   6-month\        12-month\
                                                              *n/N* (%)                                      *n/N* (%)                          *n/N* (%)       *n/N* (%)

  Primary outcome: high-risk prescribing    70/870 (8.0)      47/807 (5.8);\        0.030.04                 62/757 (8.2);\      0.90.7         71/890 (8.0)    101/1026 (9.8)
                                                              52/870 (6.0) LVCF                              74/870 (8.5) LVCF                                  

  **Secondary outcomes**                                                                                                                                        

  High-risk prescribing among patients\     35/649 (5.4)      26/596 (4.4);\        0.40.4                   33/554 (6.0);\      0.60.4         39/698 (5.6)    52/731 (7.1)
  with any gastrointestinal risk factor                       29/649 (4.5) LVCF                              42/649 (6.5) LVCF                                  

  High-risk prescribing amongst patients\   41/476^d^ (8.6)   22/444 (5.0);\        0.0070.008               33/414 (8.0);\      0.70.7         38/365 (10.4)   61/536 (11.4)
  with any renal risk factor                                  25/476 (5.3) LVCF                              38/476 (8.0) LVCF                                  

  High-risk prescribing among patients\     1/27 (3.7)        1/23 (4.4);\          0.91.0                   1/21 (4.8);\        0.91.0         1/26 (3.9)      1/25 (4.0)
  with congestive heart failure                               1/27 (3.7) LVCF                                1/27 (3.7) LVCF                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Patients vulnerable at baseline; that is at increased risk of adverse drug events (ADE) when prescribed NSAID and/or antiplatelet medicines (see [Table 1](#tbl1){ref-type="table"}). ^b^All practice vulnerable patients; that is includes patients who were not vulnerable at baseline but who have become so at 6 months and/or 12 months. ^c^Compared with baseline.^d^32/870 (3.7%) patients were included as at-risk of ADE due to a low eGFR, where it could not be confirmed that the latest eGFR was still \<60. LVCF = last value carried forward, which assumes that those lost to follow-up (left the practice or died) had the same high-risk prescribing status as baseline.

![High-risk prescribing rates in study population (vulnerable at baseline) for each high-risk category and combined. BL = baseline.](bjgpopen-1-594-g001){#fig1}

Discussion {#s5}
==========

Summary {#s5-1}
-------

The SPACE intervention was designed to foster patient engagement in medicines management and prompt medicines review. Results from this pilot study were encouraging in the short-term. SPACE was feasible within existing primary care structures; the data collection, encryption processes, and outcome measures worked well; and there were statistically significant improvements. There was a reduction in the rate of high-risk prescribing in the study population at 6 months post-intervention, but these improvements were not evident at 12 months.

Strengths and limitations {#s5-2}
-------------------------

This was a pilot study and there was no control group. Therefore, an RCT is needed to test whether any improvements in prescribing were due to the intervention. A cluster RCT began in 2018.^[@bib27]^ Data collection methods became more refined over the 12 months, particularly around the date of eGFR, which may have influenced the inclusion criteria of 32/870 (3.7%) patients at baseline. This is unlikely to have altered results, and has led to an improved data collection and assessment method for the main trial.

Comparison with existing literature {#s5-3}
-----------------------------------

Findings from this pilot study suggest SPACE may have a similar effect on prescribing to that in the PINCER trial, in that the effect was greatest at 6 months' follow-up with a slackening off by 12 months.^[@bib20]^

The novel aspect of the SPACE intervention is that SPACE explicitly aims to engage patients, but GPs opted to send the mail-out to only a minority of patients. Findings from qualitative research suggest both GPs and patients find the mail-out useful and acceptable, and that the most common reason for not sending the mail-out to a patient on the list was that the high-risk prescribing had already ceased.^[@bib26]^ It was not possible to refine the computer search to exclude prescriptions for short-courses or gel NSAIDs. Data were not collected on the proportion of patients who responded to the mail-out.

Implications for research and practice {#s5-4}
--------------------------------------

Findings from this research have informed the development of a new tool, SPACE, which can be tested as an ongoing quality improvement tool to support safer prescribing in New Zealand general practice. SPACE has the advantage of being feasible within existing primary care structures. If effective, PHOs could roll out and use SPACE regularly in practices to support safer prescribing. Similar large-scale approaches have been used successfully elsewhere.^[@bib18]--[@bib20],[@bib24]^

Results from this pilot study suggest that audit, education, and patient prompting may help support safer prescribing of NSAIDs and antiplatelet medicines. However, findings also suggest this effect may be short-lived, suggesting the intervention may need to be used regularly in practices to sustain change. Despite the drop-off in effect at 12 months, it was decided to confirm the effect of this one-off brief intervention in a large cluster RCT, which commenced early 2018. In practice, SPACE could be used repeatedly, addressing the same or a different prescribing topic every few months. Ultimately, the aim is to reduce the incidence of related ADEs, particularly those leading to hospitalisation or death, which will also be tracked in the cluster RCT, and particularly among older adults who make up the majority of vulnerable patients.
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[^1]: ^a^Patients with one or more risk factor for gastrointestinal, renal, or cardiac adverse effects when prescribed NSAID and/or antiplatelet medicines. SD = standard deviation.
